Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 10,627 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Bladder Cancer, Bladder Disease, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer, Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma, Locally Advanced Solid Tumor, Neoplasms, Neoplasm Metastasis, Neoplasm Malignant, Neoplasm, Bladder, Urothelial Neoplasm, Neoplasm, Urinary Bladder, Bladder Neoplasm, Bladder Urothelial Carcinoma
Interventions: IK-175, IK-175 and nivolumab; Drug
Lead sponsor: Ikena Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more

Conditions: Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions: Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 49 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 121
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more

Conditions: Systemic Lupus Erythematosus
Interventions: estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older · Female only
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Video recording, Notes Instruction; Behavioral
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more

Conditions: Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
Interventions: Docetaxel, Leucovorin, Fluorouracil, Cisplatin, Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen, Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 15
States / cities: Duarte, California • Pembroke Pines, Florida • Atlanta, Georgia + 11 more

Conditions: Cystic Fibrosis
Interventions: Aeroquin, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 95
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 82 more

Conditions: Abortion in First Trimester
Interventions: Dextromethorphan Hydrobromide, Avicel PH101 (Microcrystalline Cellulose NF) for Compounding, Oxycodone; Drug
Lead sponsor: Study Investigator-Sponsor; Other
Eligibility: 18 Years and older · Female only
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Urothelial Cancer and Other Malignant Solid Tumors
Interventions: enfortumab vedotin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Stanford, California • Aurora, Colorado + 14 more

Conditions: Depression, Depressive Disorder, Bipolar Disorder
Interventions: High dosage electroconvulsive therapy, Nortriptyline, Venlafaxine, Lithium, Low dosage electroconvulsive therapy; Procedure · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 4
States / cities: St Louis, Missouri • New York, New York • Winston-Salem, North Carolina + 1 more

Conditions: Osteopenia
Interventions: Melatonin 5 mg, Osteogenic loading, Mock for Osteogenic Loading, Placebo (plant fiber) for melatonin; Drug · Device
Lead sponsor: Duquesne University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Huntington's Disease
Interventions: coenzyme Q10, placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 41
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 37 more

Conditions: Acute Renal Failure
Interventions: renal replacement therapy; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 22
States / cities: No. Little Rock, Arkansas • San Francisco, California • West Los Angeles, California + 19 more

Conditions: Substance Withdrawal Syndrome
Interventions: Melatonin, Matched Placebo; Dietary Supplement
Lead sponsor: Duquesne University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions: Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Pulmonary Arterial Hypertension
Interventions: Cicletanine, Cicletanine Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Mucositis
Interventions: Low Level Laser Therapy; Device
Lead sponsor: David A. Clump, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Tucson, Arizona • Duarte, California • Glendale, California + 33 more

Conditions: Disease, Hodgkin
Interventions: brentuximab vedotin, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 32
States / cities: Duarte, California • San Francisco, California • Stanford, California + 26 more

Conditions: HIV Infections
Interventions: Dapivirine Vaginal Ring, Maraviroc Vaginal Ring, Placebo Vaginal Ring, Dapivirine-Maraviroc Vaginal Ring; Drug · Other
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Headache, Migraine
Interventions: ethosuximide, placebo comparator; Drug · Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: vildagliptin, sitagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more

Conditions: Gastrointestinal Stromal Tumors
Interventions: Imatinib mesylate; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • Santa Monica, California • Washington D.C., District of Columbia + 9 more

Conditions: Anxiety Disorder, Panic Disorder
Interventions: Clinical vestibular tests; Procedure
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, pH Low Insertion Peptide-exatecan Conjugate CBX-12, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 15
States / cities: Irvine, California • Los Angeles, California • Orange, California + 11 more

Search by objective public record fields.

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Optimizing Electroconvulsive Therapy for Depression

Melatonin and Osteogenic Loading on Osteopenia

Coenzyme Q10 in Huntington's Disease (HD)

Acute Renal Failure Trial Network (ATN) Study

The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

Low-Level Laser Therapy for Prevention of Oral Mucositis

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer